Vaxart (VXRT)

Executive Summary

Vaxart is a clinical-stage biotechnology company pioneering oral recombinant pill vaccines using its proprietary delivery platform. The company aims to transform vaccine administration by eliminating needles and enabling easier distribution. Vaxart's pipeline includes candidates for influenza, norovirus, and COVID-19, with most trials in Phase 1 or 2. The most recent completed trial (2024) evaluated a bivalent norovirus vaccine (VXA-G1.1-NN + VXA-G2.4-NS) in Phase 1, demonstrating proof-of-concept for oral delivery. Despite several terminated or completed older trials, Vaxart's platform holds promise for needle-free vaccination, especially in pandemic preparedness and pediatric populations. The company is publicly traded (VXRT) with a market cap of approximately $185 million, reflecting early-stage risk and potential. Key near-term focus will be advancing the norovirus program into Phase 2 and securing partnerships or funding to support further development.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 initiation for oral norovirus vaccine50% success
• Q3 2026Regulatory guidance or FDA meeting for oral vaccine platform60% success
• H2 2026Partnership or licensing deal for oral influenza vaccine30% success